130 related articles for article (PubMed ID: 1681090)
1. Effect of D1 and D2 agonists and antagonists on dyskinesia produced by L-dopa in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys.
Gomez-Mancilla B; Bédard PJ
J Pharmacol Exp Ther; 1991 Oct; 259(1):409-13. PubMed ID: 1681090
[TBL] [Abstract][Full Text] [Related]
2. Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys.
Kanda T; Jackson MJ; Smith LA; Pearce RK; Nakamura J; Kase H; Kuwana Y; Jenner P
Exp Neurol; 2000 Apr; 162(2):321-7. PubMed ID: 10739638
[TBL] [Abstract][Full Text] [Related]
3. Differential effect of selective D-1 and D-2 dopamine receptor agonists on levodopa-induced dyskinesia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine- exposed monkeys.
Blanchet P; Bédard PJ; Britton DR; Kebabian JW
J Pharmacol Exp Ther; 1993 Oct; 267(1):275-9. PubMed ID: 7901395
[TBL] [Abstract][Full Text] [Related]
4. De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset.
Pearce RK; Banerji T; Jenner P; Marsden CD
Mov Disord; 1998 Mar; 13(2):234-41. PubMed ID: 9539335
[TBL] [Abstract][Full Text] [Related]
5. Reduction of L-DOPA-induced dyskinesia by the selective metabotropic glutamate receptor 5 antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease.
Johnston TH; Fox SH; McIldowie MJ; Piggott MJ; Brotchie JM
J Pharmacol Exp Ther; 2010 Jun; 333(3):865-73. PubMed ID: 20231306
[TBL] [Abstract][Full Text] [Related]
6. Chronic L-DOPA administration induces dyskinesias in the 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine-treated common marmoset (Callithrix Jacchus).
Pearce RK; Jackson M; Smith L; Jenner P; Marsden CD
Mov Disord; 1995 Nov; 10(6):731-40. PubMed ID: 8749992
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic effects of dopamine D1/D2 receptor agonists on detrusor hyperreflexia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned parkinsonian cynomolgus monkeys.
Yoshimura N; Mizuta E; Yoshida O; Kuno S
J Pharmacol Exp Ther; 1998 Jul; 286(1):228-33. PubMed ID: 9655864
[TBL] [Abstract][Full Text] [Related]
8. Differing effects of N-methyl-D-aspartate receptor subtype selective antagonists on dyskinesias in levodopa-treated 1-methyl-4-phenyl-tetrahydropyridine monkeys.
Blanchet PJ; Konitsiotis S; Whittemore ER; Zhou ZL; Woodward RM; Chase TN
J Pharmacol Exp Ther; 1999 Sep; 290(3):1034-40. PubMed ID: 10454475
[TBL] [Abstract][Full Text] [Related]
9. Motor response to a dopamine D3 receptor preferring agonist compared to apomorphine in levodopa-primed 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeys.
Blanchet PJ; Konitsiotis S; Chase TN
J Pharmacol Exp Ther; 1997 Nov; 283(2):794-9. PubMed ID: 9353400
[TBL] [Abstract][Full Text] [Related]
10. Effect of adding the D1 agonist CY 208-243 to chronic bromocriptine treatment. I: Evaluation of motor parameters in relation to striatal catecholamine content and dopamine receptors.
Gomez-Mancilla B; Boucher R; Gagnon C; Di Paolo T; Markstein R; Bédard PJ
Mov Disord; 1993 Apr; 8(2):144-50. PubMed ID: 8474480
[TBL] [Abstract][Full Text] [Related]
11. Continuous administration decreases and pulsatile administration increases behavioral sensitivity to a novel dopamine D2 agonist (U-91356A) in MPTP-exposed monkeys.
Blanchet PJ; Calon F; Martel JC; Bédard PJ; Di Paolo T; Walters RR; Piercey MF
J Pharmacol Exp Ther; 1995 Feb; 272(2):854-9. PubMed ID: 7853204
[TBL] [Abstract][Full Text] [Related]
12. N-methyl-D-aspartate receptor antagonist and dopamine D1 and D2 agonist interactions in 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine-induced hemiparkinsonian monkeys.
Domino EF; Sheng J
J Pharmacol Exp Ther; 1993 Jan; 264(1):221-5. PubMed ID: 8093726
[TBL] [Abstract][Full Text] [Related]
13. Prevention of dyskinesia by an NMDA receptor antagonist in MPTP monkeys: effect on adenosine A2A receptors.
Morissette M; Dridi M; Calon F; Hadj Tahar A; Meltzer LT; Bédard PJ; Di Paolo T
Synapse; 2006 Sep; 60(3):239-50. PubMed ID: 16739115
[TBL] [Abstract][Full Text] [Related]
14. Role of selective D1 and D2 agonists in inducing dyskinesia in drug-naive MPTP monkeys.
Bédard PJ; Gomez-Mancilla B; Blanchette P; Gagnon C; Falardeau P; DiPaolo T
Adv Neurol; 1993; 60():113-8. PubMed ID: 8093573
[No Abstract] [Full Text] [Related]
15. Selective D2 receptor stimulation induces dyskinesia in parkinsonian monkeys.
Luquin MR; Laguna J; Obeso JA
Ann Neurol; 1992 May; 31(5):551-4. PubMed ID: 1350718
[TBL] [Abstract][Full Text] [Related]
16. Low doses of sarizotan reduce dyskinesias and maintain antiparkinsonian efficacy of L-Dopa in parkinsonian monkeys.
Grégoire L; Samadi P; Graham J; Bédard PJ; Bartoszyk GD; Di Paolo T
Parkinsonism Relat Disord; 2009 Jul; 15(6):445-52. PubMed ID: 19196540
[TBL] [Abstract][Full Text] [Related]
17. Changes of D1 and D2 dopamine receptor mRNA in the brains of monkeys lesioned with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: correction with chronic administration of L-3,4-dihydroxyphenylalanine.
Morissette M; Goulet M; Calon F; Falardeau P; Blanchet PJ; Bédard PJ; Di Paolo T
Mol Pharmacol; 1996 Nov; 50(5):1073-9. PubMed ID: 8913337
[TBL] [Abstract][Full Text] [Related]
18. Dyskinesia and wearing-off following dopamine D1 agonist treatment in drug-naive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned primates.
Blanchet PJ; Grondin R; Bédard PJ
Mov Disord; 1996 Jan; 11(1):91-4. PubMed ID: 8771074
[TBL] [Abstract][Full Text] [Related]
19. DOPA-induced "peak dose" dyskinesia: clues implicating D2 receptor-mediated mechanisms using dopaminergic agonists in MPTP monkeys.
Blanchet PJ; Gomez-Mancilla B; Bédard PJ
J Neural Transm Suppl; 1995; 45():103-12. PubMed ID: 8748615
[TBL] [Abstract][Full Text] [Related]
20. In 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates, the selective 5-hydroxytryptamine 1a agonist (R)-(+)-8-OHDPAT inhibits levodopa-induced dyskinesia but only with\ increased motor disability.
Iravani MM; Tayarani-Binazir K; Chu WB; Jackson MJ; Jenner P
J Pharmacol Exp Ther; 2006 Dec; 319(3):1225-34. PubMed ID: 16959959
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
